Advertisement

Picture Kentro Design Corporate and Web Design Berlin 650x65px
Document › Details

Cytos Biotechnology AG. (1/8/16). "Press Release: Cytos Biotechnology Ltd. Will Be Renamed Kuros Biosciences Ltd., Constitutes Its Board of Directors and Appoints Executive Officers".

Organisations Organisation Cytos Biotechnology AG
  Today Kuros Biosciences AG (SIX: KURN)
  Group Kuros (Group)
  Organisation 2 Kuros Biosurgery AG
  Group Kuros (Group)
Products Product VLP technology (virus-like particle technology)
  Product 2 KUR-111 orthobiologic product (Kuros)
Index term Index term Kuros–Cytos Biotechnology: investment, 201512–201601 reverse merger acquisition CHF160m of Kuros Biosurgery by Cytos to be renamed Kuros Biosciences
Persons Person Itin, Christian (Autolus 201603– CEO before Cytos 201211–201601 + Micromet 1999–2012 CEO + Co-founder + Zyomyx Inc)
  Person 2 Cowling, Didier (Kuros 200807 CEO)
     


Cytos Biotechnology Ltd announced today that the Board of Directors has constituted itself with Dr. Christian Itin stepping down as CEO but remaining as Chairman of the Board and Mr. Dominik Ellenrieder being appointed as the Vice Chairman of the Board. Further, the newly constituted Board elected Didier Cowling as Chief Executive Officer, Dr. Alistair Irvine as Chief Business Officer, Dr. Jason Schense as Chief Technology Officer and confirmed Harry Welten as the Chief Financial Officer. All appointments are effective upon closing of the acquisition of Kuros Biosurgery Holding AG which is expected to take place within the next few weeks.

“Yesterday, Cytos has received overwhelming support by our shareholders for the acquisition of Kuros Biosurgery Ltd. With the closing of the transaction most existing members of the Board will step down and new members of the Board of Directors have been elected. I would like to thank the outgoing Board members for their continued support and welcome the new members of the board and executive management”, commented Christian Itin, Chairman of Cytos. “We are pleased that Harry Welten will continue as Chief Financial Officer and are looking forward to forming Kuros Biosciences”.

   
Record changed: 2016-01-21

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px

More documents for Kuros (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x65px




» top